

MRI PROTOCOL HARMONIZATION FOR NEURODEGENERATION, VASCULAR DISEASES AND BRAIN INJURY: REGIONAL, PROVINCIAL AND NATIONAL COHORTS



**Christopher J.M. Scott¹, Joel Ramirez¹, Robert Bartha², Eric E. Smith³,
Stephen C. Strother⁴, Sandra E. Black¹, Simon Duchesne⁵**

¹L.C. Campbell Cognitive Neurology Research Unit, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario; ²Robarts Research Institute, Medical Biophysics, Western University, London, Ontario; ³University of Calgary, Calgary, Alberta; ⁴Rotman Research Centre, Baycrest Medical Biophysics, University of Toronto, Toronto, Ontario; ⁵Centre de Recherche de l'Institut Universitaire en Santé Mentale de Québec, Laval University, Quebec City, Quebec.



FONDATION DES MALADIES DU CŒUR ET DE L'AVC
Partenariat canadien pour le rétablissement de l'AVC




RATIONALE

- Large-scale neuroimaging projects are constantly evolving
- Extensive collaboration by diverse groups is necessary to maximize efficiency with increasingly competitive funding sources
- Great need for harmonization of imaging protocols across projects, vendor platforms (GE, Philips, Siemens) and recruitment sites
- This harmonization aims to optimize the compatibility of the imaging acquired at each scanner-site
- Allows data from many sources to be pooled and shared
- Allows for many projects to leverage the resources of others, both financially and in terms of the sometimes limited number of patients with a given condition that are available for recruitment

METHOD

- One such initiative is the Canadian Dementia Imaging Protocol (CDIP)
- Championed by a group of physicists, physicians and research coordinators from across Canada
- Represents diverse projects including:
 - Canadian Consortium for Neurodegeneration and Aging (CCNA)
 - Canadian Alliance for Healthy Hearts and Minds (CAHHM)
 - Consortium d'Identification de la Maladie d'Alzheimer – Québec (CIMAQ)
 - Ontario Brain Institute's Ontario Neurodegenerative Disease Research Initiative.
 - O2 study from the Consortium Québécois de Découverte du Médicament
 - Medical Imaging Trials Network of Canada (MITNEC) – C6
 - Toronto Dementia Research Alliance

PROTOCOL



- The protocol includes sequences applicable across many disease states such as dementia, neurodegeneration, traumatic brain injury (TBI), amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple sclerosis
- The protocol includes:
 - high-resolution 3D isotropic T1-weighted (for anatomical detail)
 - interleaved proton-density/T2 weighted image (for reliable skull-stripping and lesion detection of deep grey and white matter)
 - a fluid-attenuated inversion recovery (FLAIR) image (for quantification of white matter hyperintensities)
 - T2-star gradient echo (for detection of microbleeds)
 - diffusion tensor image (DTI - microstructural integrity and connectivity)
 - resting state blood oxygen level dependent (BOLD) functional MRI (to discern functional connectivity)

- Arterial spin labeling (ASL) to measure regional cerebral blood flow is also being considered.

IMPLICATIONS

- Other large-scale studies of AD such as the Alzheimer's Disease Neuroimaging Initiative (ADNI) have led the way to develop harmonized cross-platform protocols
- However, the sequences acquired for ADNI are more limited and don't include modern hardware and software improvements
- The ADNI population captures purer forms of Alzheimer's Disease with lower representation of SVD than encountered in a real world population
- This relates to their focus on clinical trials but diminishes the generalizability of the findings

FUTURE DIRECTIONS

- Although still in its early stages, this harmonization could result in imaging well over 15,000 Canadian participants from a wide variety of populations and will allow for an unprecedented understanding of the brain through the stages of normal aging and disease.

ACKNOWLEDGEMENTS

This project is directly and indirectly supported by the Canadian Institute for Health Research, The Heart and Stroke Foundation Canadian Partnership for Stroke Recovery, The Canadian Consortium for Neurodegeneration and Aging, The Sunnybrook Dementia Study, The Ontario Brain Institute – Ontario Neurodegenerative Disease Research Initiative, Consortium d'Identification de la Maladie d'Alzheimer – Québec, The Consortium Québécois de Découverte du Médicament, The Canadian Alliance for Health Hearts and Minds, The Medical Imaging Trials Network of Canada and the Toronto Dementia Research Alliance.

For more information or to download a copy of this poster, please visit brainlab.ca/posters or scan this QR code.

